Biosimilars are a great idea whose time has not come, at least not in the United States. “The whole rationale behind biosimilars is that they would be as effective, as […] READ MORE
With an ongoing opioid epidemic spreading across the United States, clinicians are increasingly looking for alternative pain management strategies. Virtual reality therapy has gained the attention of clinicians across a […] READ MORE
TNF blockers are big science and big business. Three TNF inhibitors are among the top seven best-selling drugs in the world. “If you thought that experimental medicine doesn’t lead to […] READ MORE
Results from a proof-of-concept study presented Monday during Plenary Session II suggest that CFZ533, a blocking, non-depleting anti-CD40 antibody, may offer a new treatment modality in clinically active primary Sjögren’s […] READ MORE
IL-6 is emerging as a key therapeutic target in chronic inflammatory diseases, including rheumatoid arthritis (RA), cancer, coronary heart disease, and Crohn’s disease. In RA, inhibiting IL-6 by blocking the […] READ MORE
When specialists work together, clinicians and patients alike can experience the positive effects. Such has been the case for a pediatric specialty clinic that has incorporated a specialty pharmacy into […] READ MORE
On the path to improved osteoarthritis (OA) management, how good is today’s map? During this year’s ARHP Distinguished Lecture: Moving Toward Better Osteoarthritis Management, Kelli D. Allen, PhD, with the […] READ MORE
When treating patients with myositis, rheumatologists must be cognizant of several considerations that could have severe — even fatal — consequences if left untreated. The 90-minute clinical symposium Hot Topics […] READ MORE
The widespread adoption of testing for antineutrophil cytoplasmic antibodies (ANCA) in clinical practice exposed limitations to the 1990 ACR-endorsed classification criteria for vasculitis. That has led to the development of […] READ MORE
This year’s Curbside Consult: Ask the Professors session tackled three tricky treatment challenges for various aspects of lupus, including resistant membranous lupus nephritis, small-fiber neuropathies, and hair loss. “There is […] READ MORE